Switch theme
Sign up to access all valuation multiples
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
1992
815
LTM Revenue $318M
LTM EBITDA $65.1M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Marksans Pharma has a last 12-month revenue (LTM) of $318M and a last 12-month EBITDA of $65.1M.
In the most recent fiscal year, Marksans Pharma achieved revenue of $307M and an EBITDA of $70.2M.
Marksans Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Marksans Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $318M | XXX | $307M | XXX | XXX | XXX |
| Gross Profit | $176M | XXX | $173M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 56% | XXX | XXX | XXX |
| EBITDA | $65.1M | XXX | $70.2M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $55.3M | XXX | $52.1M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $46.4M | XXX | $44.6M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Marksans Pharma's stock price is INR 261 (or $3).
Marksans Pharma has current market cap of INR 118B (or $1.4B), and EV of INR 115B (or $1.3B).
See Marksans Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.4B | XXX | XXX | XXX | XXX | $0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Marksans Pharma has market cap of $1.4B and EV of $1.3B.
Marksans Pharma's trades at 4.6x EV/Revenue multiple, and 19.9x EV/EBITDA.
Equity research analysts estimate Marksans Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marksans Pharma has a P/E ratio of 29.9x.
See valuation multiples for Marksans Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | 20.6x | XXX | 19.9x | XXX | XXX | XXX |
| EV/EBIT | 24.3x | XXX | 26.6x | XXX | XXX | XXX |
| EV/Gross Profit | 7.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.9x | XXX | 32.6x | XXX | XXX | XXX |
| EV/FCF | 166.1x | XXX | 373.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMarksans Pharma's last 12 month revenue growth is 20%
Marksans Pharma's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Marksans Pharma's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Marksans Pharma's rule of X is 69% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Marksans Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 19% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | 18% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 69% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marksans Pharma acquired XXX companies to date.
Last acquisition by Marksans Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Marksans Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Marksans Pharma founded? | Marksans Pharma was founded in 1992. |
| Where is Marksans Pharma headquartered? | Marksans Pharma is headquartered in India. |
| How many employees does Marksans Pharma have? | As of today, Marksans Pharma has 815 employees. |
| Is Marksans Pharma publicy listed? | Yes, Marksans Pharma is a public company listed on NSE. |
| What is the stock symbol of Marksans Pharma? | Marksans Pharma trades under MARKSANS ticker. |
| When did Marksans Pharma go public? | Marksans Pharma went public in 2002. |
| Who are competitors of Marksans Pharma? | Similar companies to Marksans Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Marksans Pharma? | Marksans Pharma's current market cap is $1.4B |
| What is the current revenue of Marksans Pharma? | Marksans Pharma's last 12 months revenue is $318M. |
| What is the current revenue growth of Marksans Pharma? | Marksans Pharma revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Marksans Pharma? | Current revenue multiple of Marksans Pharma is 4.2x. |
| Is Marksans Pharma profitable? | Yes, Marksans Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Marksans Pharma? | Marksans Pharma's last 12 months EBITDA is $65.1M. |
| What is Marksans Pharma's EBITDA margin? | Marksans Pharma's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Marksans Pharma? | Current EBITDA multiple of Marksans Pharma is 20.6x. |
| What is the current FCF of Marksans Pharma? | Marksans Pharma's last 12 months FCF is $8.1M. |
| What is Marksans Pharma's FCF margin? | Marksans Pharma's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Marksans Pharma? | Current FCF multiple of Marksans Pharma is 166.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
